A highly immunogenic C3H-derived UVinduced tumor was cotransfected with a murine transforming growth factor type .B1 (TGF-fi1) cDNA and a neomycinresistance gene. Stable clones were isolated and used in vitro and in vivo to determine the effects of endogenously produced TGF-, on cytolytic T-lymphocyte (CTL) responses. Tumor cells producing TGF-fi, though retaining expression for class I major histocompatibility complex molecules and the tumor-
specific antigen, did not stimulate primary CTL responses in vitro and were not effective in vivo for directly stimulating primary CTL or in priming for CTL responses. Furthermore, TGF-j3-producing tumors grew progressively in transiently immunosuppressed mice without losing the tumor antigen; thus, TGF-13 produced by tumors may promote escape from immune surveillance.
Transforming growth factor type 8 (TGF-P) is secreted in an inactive or latent form; activated TGF-,B powerfully suppresses T-and B-lymphocyte activation/differentiation but has little effect on lymphocyte proliferation once immune responses are initiated and does not suppress effector functions of activated lymphocytes such as cytolysis (1) (2) (3) (4) (5) . The evidence for immunoregulation by TGF-,8 is based almost entirely on studies using TGF-,B activated exogenously, usu- ally by acidification at pH 1-2 for 1 hr. To determine whether TGF-,B secreted in the latent form can be immunoregulatory, a TGF-,81 cDNA driven by the simian virus 40 early promoter was transfected into a highly immunogenic, C3H-derived, UV-induced fibrosarcoma, designated 1591. The 1591 tumor is highly immunogenic and expresses three major histocompatibility complex class I antigens not found in the genome of the k haplotype (6) (7) (8) . The tumors elicit a primary cytolytic T-lymphocyte (CTL) response in vitro, and tumor rejection requires CD8+ T cells, which recognize the K216 gene product (9) . Very rarely, the tumor grows progressively in normal mice but these "progressor" variants invariably have lost class I genes. A single class I molecule, K216, is sufficient for the regressor phenotype of the tumor, and transfection of K216 into progressor variants causes the tumors to be rejected (10) . Thus, the 1591 system provides a model for defining a specific CTL response against the target antigen K216 and also permits that analysis of tumor growth based on the expression of K216. The labeled by a random primer method (17) . Hybridization and posthybridization washes were performed as described (18 Sponge Matrix Allograft. Polyurethane sponges (0.5 cm3) were treated as previously described (22) Cytolytic Activity. Effector cell lysis of target cells was measured in a 4-hr 51Cr release assay by using labeling procedures, culture conditions, and calculations of specific lysis as described (23) . (Upper) The blot was probed with a 32P-labeled mouse TGF-P1 cDNA and exposed to Kodak XAR film for 9 hr at -70°C. The probe was stripped from the blot, and the blot was exposed to radiographic film for 72 hr, revealing no residual signal.
RESULTS
(Lower) The blot was reprobed with the EcoRI/Xho I 527-base-pair insert from the pSVTGF-,81 vector, which contains a portion of the rabbit (-globin sequence, and exposed to XAR film for 5 hr at -70°C. 28S and 18S ribosomal RNA sizes are given for reference.
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colonies isolated from independent transfections were screened for TGF-,p production. The increase in TGF-P production was the result of an increase in TGF-,81 transcription as shown by Northern blot analysis (Fig. 1C) 15 (Fig. 2B) . clones grew in C3H nude mice but did not grow in normal C3H mice. The 1591 tumor grows progressively in 30-40% of irradiated (400 R) mice, but progressively growing tumors invariably lost expression of the K216 antigen (G.T.A., unpublished results), an observation consistent with previous studies showing selection of tumor variants in mice partially immunosuppressed with UV radiation (24) . Furthermore, selection for antigen loss variants in partially immunosuppressed mice is the result of specific anti-1591 CTL (24, 25) . To complex in vitro (30) , and many other proteolytic agents are potential activators. Quite possibly, the activation of TGF-P and the inhibition of responses may be the result of complex interactions involving not only TGF-p-producing cells and lymphocytes but also other cells. Activated macrophages and monocytes are potential sources of both TGF-p and activators, and TGF-p may indirectly suppress immune responses by inhibiting tumor necrosis factor a production (2) and causing decreased expression of class II major histocompatibility complex molecules (31) . The 1591 tumor transfected to produce TGF-P1 failed to stimulate CTL in vitro and in vivo. The lack of response was not the result of decreased expression of endogenous class I genes or due to loss of the tumor antigen, indicating that the failure to induce primary responses was the result of TGF-P-mediated effeots on the responder cells. Almost all TGF-/3 recovered from cultured 1591-N-TGF cells was in the latent form, but presumably the 1591 tumor (and the 1591-N and 1591-N-TGF tumors as well) activates TGF-13, since the tumor reversibly acquires the same altered morphology whether cocultured with latent TGF-f3 or with activated TGF-p. The putative activator may be membrane bound, and possibly the failure to detect active TGF-p in culture supernatant of 1591-N-TGF cells occurs because almost all activated TGF-/3 is receptor bound.
Because TGF-p is so powerfully immunosuppressive, tumors producing/activating TGF-p might be expected to escape immune surveillance. 1591-N-TGF cells, however, did not grow progressively in normal recipients, presumably because a fraction ofCTL specific for K216 antigen escaped initial suppression by TGF-,B and expanded to become sufficient to cause tumor rejection. The tumor, nevertheless, did not grow progressively in transiently immunosuppressed mice and escaped selection for antigen loss variants, indicating that TGF-,B production by a tumor may be important in determining whether the tumor disappears or grows progressively.
